What FDA-Regulated Companies Should Take Away (Beyond the Headline)

On January 16, 2026, the U.S. Department of Justice announced that False Claims Act (FCA) settlements and judgments for Fiscal Year 2025 exceeded $6.8 billion, the highest annual total in the statute’s history. Recoveries more than doubled FY 2024 results, driven overwhelmingly by healthcare enforcement. The FY 2025 results reflect not only higher recoveries but also a DOJ enforcement posture increasingly comfortable advancing broader FCA theories tied to compliance representations, operational controls, and corporate decision-making.

For medical device, pharmaceutical, and other FDA-regulated companies, the headline figure matters less than what it reflects: broader FCA theories, continued reliance on whistleblowers, and closer scrutiny of how compliance representations align with operational reality. The FY 2025 results make clear that FCA risk is no longer episodic or limited to billing errors. It is increasingly tied to enterprise-wide decision-making.

The Enforcement Story Behind the Numbers

Healthcare accounted for approximately $5.7 billion (83%) of all FCA recoveries, confirming that life sciences remains DOJ’s primary enforcement focus. At the same time, a record 1,297 qui tam actions were filed, underscoring that whistleblowers remain the primary engine of FCA enforcement and often surface issues well before companies identify them internally.

DOJ has also continued to expand the framing of FCA...

Read Full Story: https://news.google.com/rss/articles/CBMihAFBVV95cUxPdmFsRGZTd3pKQU5ZaWVLOHBC...